公开(公告)号：US20230391775A1

公开(公告)日：2023-12-07

申请号：US18250799

申请日：2021-10-27

申请人： SUZHOU YABAO PHARMACEUTICAL R&D CO., LTD.

发明人： Yan XIA ,  Zengshan GUO ,  Ziqing JIANG ,  Xizhi WANG ,  Taotao ZHU ,  Chuan WANG ,  Lang ZHUO

IPC分类号： C07D471/04 ,  C07D519/00 ,  C07D413/12 ,  A61P25/28 ,  A61P25/16

CPC分类号： C07D471/04 ,  C07D519/00 ,  C07D413/12 ,  A61P25/28 ,  A61P25/16

摘要： A compound represented by formula (I), and a racemate, a stereoisomer, a tautomer, an isotopic label, an N-oxide, a hydrate, a solvate, a polymorph, a metabolite, a pharmaceutically acceptable salt, a pharmaceutically acceptable ester, or a prodrug compound thereof are provided. This class of compounds has a good LRRK2 kinase regulation and inhibition and can be used for the treatment of an LRRK2 kinase activity-associated conditions and diseases, such as proliferative diseases, protein kinase-associated diseases, lysosomal diseases, Tau diseases, and diseases caused by decreased dopamine levels. etc.

公开(公告)号：US11827695B2

公开(公告)日：2023-11-28

申请号：US17152051

申请日：2021-01-19

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： Michael K. Ahlijanian ,  Jere Ernest Meredith, Jr. ,  Nino Devidze ,  John David Graef ,  Edward L. Halk

IPC分类号： C07K16/18 ,  A61K39/395 ,  A61P25/16 ,  A61P25/28

CPC分类号： C07K16/18 ,  A61K39/3955 ,  A61P25/16 ,  A61P25/28 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/92

摘要： Disclosed herein are anti-α-synuclein antibodies which preferentially bind to oligomeric α-synuclein over monomeric α-synuclein, therapeutic compositions comprising the antibodies, and methods of using the antibodies to treat synucleinopathies.

公开(公告)号：US11826405B2

公开(公告)日：2023-11-28

申请号：US17006685

申请日：2020-08-28

申请人： AEON Biopharma, Inc.

发明人： Gregory F. Brooks ,  Andrew M. Blumenfeld

IPC分类号： A61K38/48 ,  A61P25/06 ,  A61P25/16

CPC分类号： A61K38/4893 ,  A61P25/16 ,  C12Y304/24069

摘要： Disclosed herein are compositions and methods for use in treating headache.

公开(公告)号：US20230346947A1

公开(公告)日：2023-11-02

申请号：US17987137

申请日：2022-11-15

申请人： CASE WESTERN RESERVE UNIVERSITY

发明人： Bradley T. Lang ,  Jared M. Cregg ,  Jerry Silver ,  Yi-Lan Weng

IPC分类号： A61K47/42 ,  A61P25/16 ,  A61P25/28 ,  A61K9/00 ,  A61K38/16 ,  A61K47/64 ,  A61K38/17

CPC分类号： A61K47/42 ,  A61P25/16 ,  A61P25/28 ,  A61K9/0019 ,  A61K38/162 ,  A61K47/645 ,  A61K38/179 ,  A61K2121/00

摘要： A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.

公开(公告)号：US20230330063A1

公开(公告)日：2023-10-19

申请号：US18339172

申请日：2023-06-21

申请人： Consejo Superior de Investigaciones Científicas (CSIC) ,  Universidad Autónoma de Madrid ,  CENTRO DE INVESTIGATIÓN BIOMÉDICA EN RED DE ENFERMEDADES NEURODEGENERATIVAS ,  Terran Biosciences Inc. ,  Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

发明人： Ana Maria Perez Castillo ,  Jordi Riba Serrano ,  Jose Angel Morales Garcia

IPC分类号： A61K31/4045 ,  A61P25/16 ,  A61K31/496 ,  A61K31/519

CPC分类号： A61K31/4045 ,  A61P25/16 ,  A61K31/496 ,  A61K31/519

摘要： Combination product for the treatment of neurological and/or psychiatric disorders The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.

公开(公告)号：US20230330015A1

公开(公告)日：2023-10-19

申请号：US18175599

申请日：2023-02-28

申请人： DIZLIN PHARMACEUTICALS AB

发明人： Elias ERIKSSON ,  Nil DIZDAR SEGRELL ,  Mats EHRNEBO ,  Leif BRING

IPC分类号： A61K9/08 ,  A61K9/00 ,  A61K31/198 ,  A61K47/12 ,  A61P25/16 ,  A61K47/02 ,  A61K47/26 ,  A61P25/00 ,  A61K47/18 ,  A61K47/40

CPC分类号： A61K9/08 ,  A61K9/0019 ,  A61K31/198 ,  A61K47/12 ,  A61P25/16 ,  A61K47/02 ,  A61K47/26 ,  A61P25/00 ,  A61K47/18 ,  A61K47/40 ,  A61K45/06

摘要： An aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), comprises at least 5 mg/ml dissolved levodopa and has a pH in the range of 3.0 to 8.5. The solution is provided by mixing a) an aqueous stock solution comprising levodopa and having a pH of less than 2.8 at 25° C., and b) an aqueous buffering solution having a pH of at least 4.0 at 25° C. for increasing the pH of the stock solution. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the CNS shortly after mixing of the aqueous stock solution and the aqueous buffering solution. A kit for administration of the aqueous pharmaceutical solution includes a bag comprising two parts and a removable or perforable barrier between the two parts.

公开(公告)号：US11771657B2

公开(公告)日：2023-10-03

申请号：US17522687

申请日：2021-11-09

申请人： Peptron, Inc. ,  The United States, as represented by the Secretary, Department of Health and Human Services

发明人： Dong Seok Kim ,  Hee Kyung Kim ,  Nigel H. Greig

IPC分类号： A61K9/50 ,  A61P25/28 ,  A61P25/30 ,  A61P25/16 ,  A61K9/00 ,  A61K9/48 ,  A61K38/26 ,  A61M5/142

CPC分类号： A61K9/5031 ,  A61K9/0019 ,  A61K9/4866 ,  A61K38/26 ,  A61M5/14228 ,  A61P25/16 ,  A61P25/28 ,  A61P25/30

摘要： The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject. The method includes administering to the systemic blood circulation of the subject a therapeutically effective amount of a neuroprotective polypeptide by a controlled-release formulation or a device providing a sustained release of the neuroprotective polypeptide including at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analogue; the neuroprotective polypeptide binds to and activates a receptor that binds at least one of GLP-1, exendin-4, or a combination thereof; and the controlled-release neuroprotective formulation or the sustained release of the neuroprotective polypeptide enhances the delivery of the neuroprotective polypeptide across a blood-brain barrier (BBB) of the subject to at least a portion of the CNS relative to a rapid release formulation of the neuroprotective polypeptide. Also disclosed is a method of treating a subject with a CNS-related disease or reducing at least one symptom of a CNS-related disease in a subject in need thereof.

公开(公告)号：US20230302046A1

公开(公告)日：2023-09-28

申请号：US18314442

申请日：2023-05-09

申请人： METIMEDI PHARMACEUTICALS CO., LTD.

发明人： Chong-Hwan CHANG ,  Keun-Yeong JEONG

IPC分类号： A61K33/06 ,  A61K47/36 ,  A61P29/00 ,  A61P9/10 ,  A61P25/16 ,  A61P25/28 ,  A61K31/19 ,  A61K9/00 ,  A61P1/16

CPC分类号： A61K33/06 ,  A61K47/36 ,  A61P29/00 ,  A61P9/10 ,  A61P25/16 ,  A61P25/28 ,  A61K31/19 ,  A61K9/00 ,  A61P1/16

摘要： The invention relates to method of treating chronic inflammatory diseases in subjects in need thereof by administering calcium lactate as an active agent. The calcium lactate can be provided in a pharmaceutical, food, or nutrient composition.

公开(公告)号：US20230287358A1

公开(公告)日：2023-09-14

申请号：US18298529

申请日：2023-04-11

申请人： Prevail Therapeutics, Inc.

发明人： Asa ABELIOVICH ,  Laura HECKMAN ,  Herve RHINN

IPC分类号： C12N7/00 ,  C07K14/47 ,  A61P25/28 ,  A61K9/00 ,  A61K35/76 ,  A61K48/00 ,  C07K14/005 ,  C07K14/61 ,  C07K14/705 ,  A61P25/16 ,  C07K14/435 ,  A61K35/761 ,  C12N15/861

CPC分类号： C12N7/00 ,  C07K14/47 ,  A61P25/28 ,  A61K9/0019 ,  A61K9/0085 ,  A61K35/76 ,  A61K48/0058 ,  C07K14/005 ,  C07K14/61 ,  C07K14/70503 ,  A61P25/16 ,  A61K48/0075 ,  C07K14/435 ,  A61K35/761 ,  C12N15/861 ,  C12N2750/14121 ,  C12N2750/14122 ,  C12N2750/14143 ,  C12N15/86

摘要： The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease (PD) and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding beta-Glucocerebrosidase (GBA) or a portion thereof alone or in combination with one or more PD-associated genes. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.

公开(公告)号：US11752110B2

公开(公告)日：2023-09-12

申请号：US15312433

申请日：2015-05-20

申请人： LTS LOHMANN Therapie-Systeme AG

发明人： Marco Emgenbroich ,  Johannes Josef Leonhard ,  Kristina Kassner ,  Aurélia Lappert

IPC分类号： A61K9/70 ,  A61K47/34 ,  A61K47/02 ,  A61K9/00 ,  A61K31/381 ,  A61P21/00 ,  A61P25/00 ,  A61P25/16 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28

CPC分类号： A61K9/7069 ,  A61K9/0014 ,  A61K9/7038 ,  A61K31/381 ,  A61K47/02 ,  A61K47/34 ,  A61P21/00 ,  A61P25/00 ,  A61P25/16 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28

摘要： Transdermal therapeutic system for the transdermal administration of a systemically active agent comprising a self-adhesive layer structure, comprising A) a backing layer, and B) a dried biphasic layer, the dried biphasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or polymer mixture, and b) an inner phase having a composition comprising at least one active agent, wherein the inner phase forms dispersed deposits in the outer phase, and c) 0.1% to 3.5% of an interface mediator with a kinematic viscosity of from 10 cSt to 100 000 cSt at 25° C., and C) optionally an additional skin contact layer.